Enzymatic Implications and Biochemical Assessments of Doxorubicin (DXR) in TCA-induced Neoplasia Wistar Rats
Olufemi SF, Bimpe FO, Christopher EOI, Micheal IN
Despite decades of attempt to curb the menace of cancer and the analogous chemotherapy, the disease remains one of the most dreadful with high annual mortality rate. Trichloroacetic acid (TCA) is a micro-contaminant of groundwater with carcinogenic effect. The effect of relatively low dose of doxorubicin (DXR) was examined in the body chemistry of early and late TCA cancer induced Wistar rats; the internal tissues were used to assay for glucose, albumin, total protein, peptidase, ALT, LDH, ACP and ALP. TCA induced multineoplasia in the tested rats and this was characterized with tissues atrophy as manifested in the elevated level of serum protein and peptidase activity; similar to the adopted treatments but seemed to have positively modulated the liver total protein. Serum and liver glucose levels remained unaffected. Oral gavage of TCA caused hypoalbuminemia and hyperalbuminemia in the serum and kidney, but there was no significant effect (P>0.05) in the heart. Generally, adopted treatments stimulated peptidase activity in serum with high level of protein and albumin in serum and kidney respectively. There was no significant alteration in ACP and ALP. ALT, which appeared to be elevated and reduced in the liver and serum respectively, was moderated by the adopted treatments. Likewise, the elevated LDH activity was reduced by the treatments but its activity was extremely insignificant in the kidney. Therefore, irrepressible consumption of TCA contaminated water may result into neoplasia. DXR, at relatively low dose, may be useful in the management of cancer without causing insufferable physiological changes.
Cancer, Doxorubicin, TCA, Enzymes, Proteins, Glucose
Cite This Article
Olufemi, S. F., Bimpe, F. O., Christopher, E. O. I., & Micheal, I. N. (2014). Enzymatic Implications and Biochemical Assessments of Doxorubicin (DXR) in TCA-induced Neoplasia Wistar Rats. International Journal for Pharmaceutical Research Scholars, 3(1), 854 to 863.